Showing results (1-10 of 319) with videos related to
Sort By:
Pageof 32
Urology|November 5, 2002
Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunctionJackie D Corbin, Sharron H Francis, David J WebbExpert Opinion on Drug Metabolism & Toxicology|August 23, 2006
Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunctionSharron H Francis, Jackie D CorbinThe Urologic Clinics of North America|November 18, 2005
Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunctionSharron H Francis, Jackie D CorbinCellular Signalling|May 31, 2011
Conformational conversion of PDE5 by incubation with sildenafil or metal ion is accompanied by stimulation of allosteric cGMP bindingJackie D Corbin, Sharron H FrancisCurrent Opinion in Pharmacology|September 20, 2011
PDE5 inhibitors: targeting erectile dysfunction in diabeticsSharron H Francis, Jackie D CorbinCurrent Urology Reports|November 19, 2003
Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonistsSharron H Francis, Jackie D CorbinThe Journal of Biological Chemistry|January 13, 2006
Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinityRoya Zoraghi, Jackie D Corbin, Sharron H FrancisCellular Signalling|August 12, 2009
Allosteric-site and catalytic-site ligand effects on PDE5 functions are associated with distinct changes in physical form of the enzymeJackie D Corbin, Roya Zoraghi, Sharron H FrancisBiochemistry|November 6, 2007
Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitorsRoya Zoraghi, Sharron H Francis, Jackie D CorbinPhysiological Reviews|April 30, 2011
Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functionsSharron H Francis, Mitsi A Blount, Jackie D CorbinPageof 32